Corrigendum to "synthesis and activity of substituted carbamates as potentiators of the α4β2 nicotinic acetylcholine receptor" [Bioorg. Med. Chem. Lett. 18 (2008) 5643-5647] (DOI:10.1016/j.bmcl.2008.08.092);Synthesis and activity of substituted carbamates as potentiators of the α4β2 nicotinic acetylcholine receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 20, 2008, Pages 5643-5647

  Springer, Stephanie K ^a   Woodin, Katrina S ^a   Berry, Virginia ^a   Boezio, Alessandro A ^a   Cao, Lei ^a   Clarkin, Kristie ^a   Harmange, Jean Christophe ^a   Hierl, Markus ^a   Knop, Johannes ^b   Malmberg, Annika B ^a   McDermott, Jeff S ^a   Nguyen, Hung Q ^a   Waldon, Daniel ^a   Albrecht, Brian K ^a   McDonough, Stefan I ^a  

^a AMGEN INC   (United States)

^b Amgen Research GmbH   (Germany)

Author keywords

Carbamates; Nicotinic acetylcholine receptors; Potentiators

Indexed keywords

CARBAMIC ACID DERIVATIVE; ETHER DERIVATIVE; NICOTINIC ACETYLCHOLINE ALPHA4BETA2 RECEPTOR STIMULATING AGENT; NICOTINIC RECEPTOR; PYRAZOLE CARBAMATE DERIVATIVE; PYRAZOLE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PATCH CLAMP; RAT; STRUCTURE ACTIVITY RELATION;

EID: 53349165560     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.115     Document Type: Erratum

References (26)

1. For reviews of nicotinic acetylcholine receptors and their therapeutic potential, see:. Moaddel R., Jozwiak K., and Wainer I.W. Med. Res. Rev. 27 (2007) 723
2. Romanelli M.N., Gratteri P., Guandalini L., Martini E., Bonaccini C., and Gualtieri F. ChemMedChem 2 (2007) 746
3. Breining S.R., Mazurov A.A., and Miller C.H. Ann. Rep. Med. Chem. 40 (2005) 3
4. Hogg R.C., and Bertrand D. Curr. Drug Targets 3 (2004) 123
5. Americ S.P., Holladay M., and Williams M. Biochem. Pharmacol. 74 (2007) 1092
6. Milla N.S. Biochem. Soc. Trans. 31 (2003) 869
7. Decker M.W., Meyer M.D., and Sullivan J.P. Expert Opin. Investig. Drugs 10 (2001) 1819
8. Lynch J.J., Wade C.L., Mikusa J.P., Decker M.W., and Honore P. Eur. J. Pharmacol. 509 (2005) 43
9. Coe J.W., Brooks P.R., Vetelino M.G., et al. J. Med. Chem. 48 (2005) 3474
10. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., and Williams K.E. Trends Pharmacol. Sci. 28 (2007) 316
11. Sullivan J.P., and Bannon A.W. CNS Drug Rev 2 (1996) 21
12. Jensen A.A., Frolund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 48 (2005) 4705
13. Bunnelle W.H., Dart M.J., and Schrimpf M.R. Curr. Top. Med. Chem. 4 (2004) 299
14. Holladay M.W., Dart M.J., and Lynch J.K. J. Med. Chem. 40 (1997) 4169
15. Lloyd G.K., and Williams M. J. Pharmacol. Exp. Ther. 292 (2000) 461
16. Astles P.C., Baker S.R., Boot J.R., Broad L.M., Dell C.P., and Keenan M. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 337
17. For some recent reports on selective α4β2 nAChR agonists see:. Bunnelle W.H., Daanen J.F., Ryther K.B., Schrimpf M.R., Dart M.J., Gelain A., Meyer M.D., Frost J.M., Anderson D.J., Buckley M., Curzon P., Cao Y.-J., Puttfarcken P., Searle X., Ji J., Putman C.B., Surowy C., Toma L., and Barlocco D. J. Med. Chem. 50 (2007) 3627
18. Dunbar G., Boeijinga P.H., Demazieres A., Cisterni C., Kuchibhatla R., Wesnes K., and Luthringer R. Psychopharmacology 191 (2007) 919
19. Ji J., Bunnelle W.H., Anderson D.J., Faltynek C., Dyhring T., Ahring P.K., Rueter L.E., Curzon P., Buckley M.J., Marsh K.C., Kempf-Grote A., and Meyer M.D. Biochem. Pharmacol. 74 (2007) 1253
20. Ji J., Schrimpf M.R., Sippy K.B., Bunnelle W.H., Li T., Anderson D.J., Faltynek C., Surowy C.S., Dyhring T., Ahring P.K., and Meyer M.D. J. Med. Chem. 50 (2007) 5493
21. Lam S., and Patel P.N. Cardiol. Rev. 15 (2007) 154
22. Smith J.W., Mogg A., Tafi E., Peacey E., Pullar I.A., Szekeres P., and Tricklebank M. Psychopharmacology 190 (2007) 157 (and references therein)
23. Measurement of test compound to potentiate a submaximal response to nicotine (1/8 EC50, or EC12) based on an average of n ≥ 2. For a recent report of nAChR potentiators, and assay conditions, see:. Broad L.M., Zwart R., Pearson K.H., Lee M., Wallace L., McPhie G.I., Emkey R., Hollinshead S.P., Dell C.P., Baker S.R., and Sher E. J. Pharmacol. Exp. Ther. 318 (2006) 1108
24. Transport across MDR1-LLC-PK1 cells (pig kidney cells transfected with human MDR1 gene) was carried out as described (Yamazaki et al., J. Pharmacol. Exp. Ther. 2001, 296, 723) with some modifications. Briefly, MDR1-LLC-PK1 cells were plated at a density of 200,000 cells/well on membrane filters (24-well Transwells, Millipore, Cambridge, MA). Transport was performed manually in basolateral to apical (B to A) and apical to basolateral (A to B) directions in the presence of 0.1% bovine serum albumin on the fifth day after plating. Efflux ratio was determined as the transport ratio of B to A versus A to B at 5 μM after a 2-h incubation.
25. 1H NMR. Additional NMR studies were employed as necessary.
26. Enantiomerically enriched epoxide obtained from HKR.